PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsApomorphine
Apokyn, Uprima(apomorphine)
Apokyn, Apomorphine, Ixense, Taluvian, Uprima (apomorphine) is a small molecule pharmaceutical. Apomorphine was first approved as Uprima on 2001-05-28. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat erectile dysfunction. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2B, alpha-2B adrenergic receptor, transient receptor potential cation channel subfamily A member 1, D(1A) dopamine receptor, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
urogenital diseasesD000091642
mental disordersD001523
Trade Name
FDA
EMA
Apokyn, Kynmobi (generic drugs available since 2022-02-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Apomorphine hydrochloride
Tradename
Company
Number
Date
Products
APOKYNMDD US OperationsN-021264 RX2004-04-20
1 products, RLD, RS
KYNMOBISunovion PharmaceuticalsN-210875 RX2020-05-21
5 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
apokynNew Drug Application2023-12-20
apomorphine hydroclorideANDA2022-02-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
Agency Specific
FDA
EMA
Expiration
Code
APOMORPHINE HYDROCHLORIDE, KYNMOBI, SUNOVION PHARMS INC
2023-05-21NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Apomorphine Hydrochloride, Kynmobi, Sunovion Pharms Inc
104491462036-04-19U-2825
109599432036-04-19U-2825
84149222031-12-16DPU-2825
88460742031-12-16DPU-2825
114197692031-12-16DPU-2825
90444752030-06-11DP
92832192030-06-11DPU-2825
93269812030-06-11U-2825
96690192030-06-11DPU-2825
96690212030-06-11U-2825
104207632030-06-11DPU-2825
108210742029-08-07DP
86035142024-04-03DP
87651672024-02-20DP
86636872023-02-02DP
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BE: Drugs used in erectile dysfunction
— G04BE07: Apomorphine
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BC: Dopamine agonists
— N04BC07: Apomorphine
HCPCS
Code
Description
J0364
Injection, apomorphine hydrochloride, 1 mg
Clinical
Clinical Trials
59 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20215186846
Low back painD017116HP_0003419M54.5———1—1
Restless legs syndromeD012148EFO_0004270G25.81———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Consciousness disordersD003244———21——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HallucinationsD006212HP_0000738F06.0—1———1
Brain injuriesD001930—S06.9—1———1
AlcoholismD000437EFO_0003829F10.1—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20————11
Progressive supranuclear palsyD013494EFO_0002512G23.1————11
Corticobasal degenerationD000088282—G31.85————11
Attention deficit disorder with hyperactivityD001289EFO_0003888F90————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameApomorphine
INN—
Description
Apomorphine is an aporphine alkaloid. It has a role as an alpha-adrenergic drug, a serotonergic drug, an antidyskinesia agent, a dopamine agonist, an antiparkinson drug and an emetic. It derives from a hydride of an aporphine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3
Identifiers
PDB—
CAS-ID58-00-4
RxCUI—
ChEMBL IDCHEMBL53
ChEBI ID48538
PubChem CID6005
DrugBankDB00714
UNII ID—
Target
Agency Approved
DRD3
DRD3
DRD4
DRD4
DRD2
DRD2
Organism
Homo sapiens
Gene name
DRD3
Gene synonyms
NCBI Gene ID
1814
Protein name
D(3) dopamine receptor
Protein synonyms
Dopamine D3 receptor, essential tremor 1
Uniprot ID
Q4VBM8
Mouse ortholog
Drd3 (13490)
D(3) dopamine receptor (P30728)
Alternate
HTR2B
HTR2B
ADRA2B
ADRA2B
TRPA1
TRPA1
DRD1
DRD1
DRD5
DRD5
HTR2A
HTR2A
HTR1A
HTR1A
HTR2C
HTR2C
ADRA2A
ADRA2A
ADRA2C
ADRA2C
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
3357
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Q6P523
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Apokyn – Supernus Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 10,558 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,016 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use